- Home
- IROH vs MDXH Comparison
IROH vs MDXH Comparison
Compare IROH & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IROH
- MDXH
- Stock Information
- Founded
- IROH 2021
- MDXH 2003
- Country
- IROH United States
- MDXH Belgium
- Employees
- IROH N/A
- MDXH N/A
- Industry
- IROH
- MDXH
- Sector
- IROH
- MDXH
- Exchange
- IROH Nasdaq
- MDXH Nasdaq
- Market Cap
- IROH 92.3M
- MDXH 93.1M
- IPO Year
- IROH 2023
- MDXH 2021
- Fundamental
- Price
- IROH $10.41
- MDXH $1.86
- Analyst Decision
- IROH
- MDXH Strong Buy
- Analyst Count
- IROH 0
- MDXH 2
- Target Price
- IROH N/A
- MDXH $7.00
- AVG Volume (30 Days)
- IROH 30.6K
- MDXH 58.0K
- Earning Date
- IROH 01-01-0001
- MDXH 02-26-2025
- Dividend Yield
- IROH N/A
- MDXH N/A
- EPS Growth
- IROH N/A
- MDXH N/A
- EPS
- IROH N/A
- MDXH N/A
- Revenue
- IROH N/A
- MDXH $84,708,000.00
- Revenue This Year
- IROH N/A
- MDXH $28.76
- Revenue Next Year
- IROH N/A
- MDXH $19.91
- P/E Ratio
- IROH $67.09
- MDXH N/A
- Revenue Growth
- IROH N/A
- MDXH 33.01
- 52 Week Low
- IROH $9.97
- MDXH $1.55
- 52 Week High
- IROH $11.11
- MDXH $3.85
- Technical
- Relative Strength Index (RSI)
- IROH N/A
- MDXH 41.65
- Support Level
- IROH N/A
- MDXH $1.82
- Resistance Level
- IROH N/A
- MDXH $2.01
- Average True Range (ATR)
- IROH 0.00
- MDXH 0.09
- MACD
- IROH 0.00
- MDXH 0.01
- Stochastic Oscillator
- IROH 0.00
- MDXH 46.43
About IROH Iron Horse Acquisitions Corp. Common Stock
Iron Horse Acquisitions Corp is a blank check company.
About MDXH MDxHealth SA
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA), and Europe.